Abstract: Cardiovascular toxicity associated with targeted therapy for lung cancer is not rare. Arrhythmias may be the most prominent cardiovascular toxicities, among which prolonged QT interval is the most harmful. In patients treated with osimertinib and anaplastic lymphoma kinase (ALK) inhibitors, special attention should be paid to the adverse effects of prolonged QT interval. Hypertension is a cardiovascular toxicity that should be considered in patients receiving anti-VEGF treatment and third-generation ALK inhibitors. The cardiotoxicity of HER-2-targeted drugs is not serious. The incidence of peripheral edema is high in patients receiving MET and ROS-1 inhibitors. Thus, oncologists should pay more attention to monitoring and managing cardiovascular complications in patients receiving targeted therapy.